Filing Flows › Ensysce Biosciences (ENSC) › Q4 2024
Ensysce Biosciences (ENSC) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Mar 10, 2025
Ensysce Biosciences (ENSC) reported revenue of $1.3M for the fourth quarter 2024 (Q4 2024), +153% from a year earlier and -62% from the quarter before. Operating margin was -274.3%, net loss $3.6M (273.4% of revenue).
Ensysce Biosciences, Q4 2024: revenue $1.3M (+153% year over year), operating margin -274.3%, net loss $3.6M, operating cash flow −$764K. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.3M | -62% | +153% |
| Operating profit | −$3.6M | — | — |
| Net earnings | −$3.6M | — | — |
| Operating cash flow | −$764K | — | — |
What changed
Revenue was $1.3M in Q4 2024, up 153% year over year and down 62% from the previous quarter.
Operating costs exceeded revenue by $3.6M, an operating margin of -274.3%. Total costs grew 33% against revenue growth of 153%. The fastest-growing cost line was Research & development (+70%). The quarter ended with a net loss of $3.6M, after a profit of $662K the previous quarter.
Operating cash flow was −$764K. Non-cash charges added back $30K of share-based compensation. Working capital and other items added $2.8M.
Questions
What was Ensysce Biosciences' revenue in the fourth quarter 2024?
Ensysce Biosciences (ENSC) reported revenue of $1.3M for the fourth quarter 2024 (Q4 2024), +153% from a year earlier and -62% from the quarter before.
Was Ensysce Biosciences profitable in the fourth quarter 2024?
Operating loss was $3.6M (-274.3% of revenue) and net loss $3.6M.